Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day. Health and pharmaceutical stocks — including Moderna (MRNA), Pfizer ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

Materials and methods: Here, we developed a novel bivalent mRNA vaccine ... We also tested RBMRNA-405 as a booster shot following two doses of inactivated whole-virion WA1/2020 SARS-CoV-2 vaccine ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and ...

Inovio Pharmaceuticals Inc.-2.00% $72.2M ...

Bitte entschuldigen Sie den Fehler. Sollte dieser Fehler erneut auftreten, kontaktieren Sie bitte unseren Kundeservice per E-Mail.